secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-10-09T20:30:23+00:00
Accession:  0001493152-26-046546
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 9.01, 3.02, 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO
--------------------------------------------------------------------------------

- Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.
- The Purchase Agreement caps issuance at 19.99% of post-issuance outstanding shares, with any reduction settled in cash; shares have a six-month lock-up and piggyback registration rights.
- At closing Hepion paid Canton $1,000,000 and GLS paid $125,000 toward the Canton Seller Note; Hepion became sole obligor/guarantor of remaining obligations.
- Four Hepion directors, including Stetz and Appajosyula, are GLS officers/Sole Member shareholders and recused themselves; disinterested directors approved with a Ryan Valuation fairness opinion.
- Effective Oct. 9, 2026, Sireesh Appajosyula became CEO and Gary Stetz became CFO; Appajosyula was Gravitas Life Sciences' former CEO and Stetz was Hepion's interim CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/0001493152-26-046546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226046546/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer